Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.

scientific article published on 21 August 2013

Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/13506129.2013.825240
P698PubMed publication ID23964755
P5875ResearchGate publication ID256075184

P50authorLuc HittingerQ21055496
P2093author name stringJean-Pascal Lefaucheur
Stéphane Moutereau
Sylvain Loric
Thibaud Damy
Aziz Guellich
Violaine Plante-Bordeneuve
Dania Mohty
Jean-François Deux
Soulef Guendouz
Stéphane Rappeneau
P2860cites workUniversal definition of myocardial infarctionQ34007701
Biomarkers of cardiovascular disease: molecular basis and practical considerationsQ34526561
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.Q35002777
Tissue Doppler imaging in the evaluation of left ventricular diastolic functionQ35865679
Transthyretin-related familial amyloidotic polyneuropathyQ36189972
Amyloidosis and the heart: a comprehensive reviewQ36603755
Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomesQ36846286
Recommendations for the evaluation of left ventricular diastolic function by echocardiographyQ37383745
Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosisQ37909598
Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experienceQ38172331
The systemic amyloidosesQ41596634
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponinsQ44022591
Diagnostic efficiency of troponin T measurements in acute myocardial infarctionQ46657809
Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac functionQ47310426
Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patientsQ48270711
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosisQ48323509
Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosisQ48404782
Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosisQ48496969
The value of BNP testingQ48527750
Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?Q48765394
Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure.Q51799502
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of EchocardioQ57217547
Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?Q57259435
Outcome of exerciseelectrocardiographyin familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantationQ57259455
P433issue4
P304page(s)212-220
P577publication date2013-08-21
P1433published inAmyloidQ4749545
P1476titleRole of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis
P478volume20

Reverse relations

cites work (P2860)
Q33168881Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options
Q35244195Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis
Q36559736Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy
Q26776496Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Q92486932Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
Q92826292Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Q40532663Identification of prognostic markers in transthyretin and AL cardiac amyloidosis
Q58104657Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
Q36338381Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Q38547033Improving strategies for the diagnosis of cardiac amyloidosis
Q58029886Molecular imaging of misfolded protein pathology for early clues to involvement of the heart
Q58125154Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study
Q59295474Patient-Specific Biomechanical Modeling of Cardiac Amyloidosis – A Case Study
Q41149554Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness
Q37009096Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis
Q57653734Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis
Q95729110Value of natriuretic peptides and tissue Doppler imaging in the estimation of left ventricular filling pressure in patients with cardiac amyloidosis
Q55425790Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.